Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.

7 equities research analysts have issued twelve-month target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $20.00 to $40.00. On average, they expect the company's stock price to reach $30.89 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.

Rhythm Pharmaceuticals' stock was trading at $29.12 at the beginning of 2023. Since then, RYTM stock has increased by 4.6% and is now trading at $30.47.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RYTM earnings forecast.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $0.22. The business had revenue of $4.28 million for the quarter, compared to analyst estimates of $5.36 million. Rhythm Pharmaceuticals had a negative net margin of 1,089.07% and a negative trailing twelve-month return on equity of 72.83%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.82%) and Hennion & Walsh Asset Management Inc. (0.11%). Insiders that own company stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends.

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RYTM stock can currently be purchased for approximately $30.47.

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.72 billion and generates $3.15 million in revenue each year. The company earns $-69,610,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis.

The company employs 140 workers across the globe.

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.